Comparable stake leader
BlackRock, Inc.
SEC ownership of Apogee Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001974640.
Disclosed value leader
Venrock Adviser, LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- APGE on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001974640
- Issuer location
- San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Apogee Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
Venrock Adviser, LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 5.5%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 5.5%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
5.5%
RTW INVESTMENTS, LP
4.9%
DRIEHAUS CAPITAL MANAGEMENT LLC
4.7%
FMR LLC
4%
T. Rowe Price Investment Manageme...
1.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
5.5%
from 13D/G
|
$730,948,292
5,507,032 shares
|
— | 30 Jun 2026 |
| RTW INVESTMENTS, LP |
13D/G
|
4.9%
|
$214,255,663
2,712,097 shares
|
$0 | 31 Dec 2025 |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
13D/G
Company
|
4.7%
from 13D/G
|
$230,963,606
1,740,101 shares
|
— | 30 Jun 2026 |
| FMR LLC |
13F
13D/G
Company
|
4%
from 13D/G
|
$330,914,038
2,493,137 shares
|
— | 30 Jun 2026 |
| T. Rowe Price Investment Management, Inc. |
13D/G
13F
Company
|
1.3%
|
$102,595,557
772,969 shares
|
-$1,263,349,841 | 30 Jun 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
13D/G
Company
|
0.9%
from 13D/G
|
$74,902,989
564,326 shares
|
— | 30 Jun 2026 |
| Venrock Adviser, LLC |
13F
Company
|
14%
|
$1,127,318,496
8,493,321 shares
|
— | 30 Jun 2026 |
| HBK INVESTMENTS L P |
13F
Company
|
4.5%
|
$378,280,500
2,850,000 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$159,161,708.
Buys
$14,999,936
Insiders: 1
Sells
$174,161,644
Insiders: 4
Net
-$159,161,708
Shares: -1,822,042
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 365,853
Shares: 2,187,895
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 137,400 | $0 | $18,244,445 | -$18,244,445 |
| 3-6 | 0 | 84,500 | $0 | $7,007,405 | -$7,007,405 |
| 6-9 | 0 | 1,853,200 | $0 | $141,119,221 | -$141,119,221 |
| 9-12 | 365,853 | 112,795 | $14,999,936 | $7,790,573 | +$7,209,363 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to Apogee Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
Nimish P. Shah
Net 12M change
-$159,161,709
Latest report
03 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Nimish P. Shah | Director | $14,999,936 | +$14,999,936 | +100% | Mixed | 03 Sep 2026 |
| Jane Pritchett Henderson | Chief Financial Officer | $0 | -$2,092,807 | -100% | Mixed | 03 Sep 2026 |
| Carl Dambkowski | Chief Medical Officer | $0 | -$10,154,032 | -100% | Mixed | 02 Sep 2026 |
| Jennifer A. Fox | Director | $0 | Mixed | 03 Sep 2026 | ||
| Mark C. McKenna | Director | $0 | Mixed | 03 Sep 2026 | ||
| Peter Evan Harwin | Director | $0 | Mixed | 03 Sep 2026 | ||
| Michael Thomas Henderson | Chief Executive Officer, Director | $0 | -$28,389,806 | -100% | Mixed | 03 Sep 2026 |
| William A. Jones Jr. | Director | $0 | Mixed | 03 Sep 2026 | ||
| Fairmount Funds Management LLC | Director | $0 | -$133,525,000 | -100% | Mixed | 03 Sep 2026 |
| Fairmount Healthcare Fund II L.P. | Director | $0 | Mixed | 03 Sep 2026 | ||
| Tomas Kiselak | Director | $0 | Mixed | 03 Sep 2026 | ||
| Andrew Gottesdiener | Director | Mixed | 17 Jun 2025 | |||
| Lisa Bollinger | Director | Mixed | 03 Sep 2026 |
Recent insider transactions for Apogee Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | APGE | Common Stock | Disposed to Issuer | -100% | -51,166 | 0 | 03 Sep 2026 | By Peter Harwin | ||
| Fairmount Funds Management LLC | APGE | Common Stock | Disposed to Issuer | -100% | -51,166 | 0 | 03 Sep 2026 | By Peter Harwin | ||
| Fairmount Funds Management LLC | APGE | Common Stock | Disposed to Issuer | -100% | -51,166 | 0 | 03 Sep 2026 | By Peter Harwin | ||
| Fairmount Funds Management LLC | APGE | Common Stock | Disposed to Issuer | -100% | -51,166 | 0 | 03 Sep 2026 | By Peter Harwin | ||
| Fairmount Funds Management LLC | APGE | Common Stock | Disposed to Issuer | -100% | -51,166 | 0 | 03 Sep 2026 | By Tomas Kiselak | ||
| Fairmount Funds Management LLC | APGE | Common Stock | Disposed to Issuer | -100% | -51,166 | 0 | 03 Sep 2026 | By Tomas Kiselak | ||
| Fairmount Funds Management LLC | APGE | Common Stock | Disposed to Issuer | -100% | -51,166 | 0 | 03 Sep 2026 | By Tomas Kiselak | ||
| Fairmount Funds Management LLC | APGE | Common Stock | Disposed to Issuer | -100% | -51,166 | 0 | 03 Sep 2026 | By Tomas Kiselak | ||
| Fairmount Funds Management LLC | APGE | Common Stock | Disposed to Issuer | -100% | -340,855 | 0 | 03 Sep 2026 | By Fairmount Healthcare Fund II LP | ||
| Fairmount Funds Management LLC | APGE | Common Stock | Disposed to Issuer | -100% | -340,855 | 0 | 03 Sep 2026 | By Fairmount Healthcare Fund II LP | ||
| Fairmount Funds Management LLC | APGE | Common Stock | Disposed to Issuer | -100% | -340,855 | 0 | 03 Sep 2026 | By Fairmount Healthcare Fund II LP | ||
| Fairmount Funds Management LLC | APGE | Common Stock | Disposed to Issuer | -100% | -340,855 | 0 | 03 Sep 2026 | By Fairmount Healthcare Fund II LP | ||
| Fairmount Funds Management LLC | APGE | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -80,246 | 0 | 03 Sep 2026 | By Tomas Kiselak | ||
| Fairmount Funds Management LLC | APGE | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -80,246 | 0 | 03 Sep 2026 | By Tomas Kiselak | ||
| Fairmount Funds Management LLC | APGE | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -80,246 | 0 | 03 Sep 2026 | By Tomas Kiselak | ||
| Fairmount Funds Management LLC | APGE | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -80,246 | 0 | 03 Sep 2026 | By Tomas Kiselak | ||
| Fairmount Funds Management LLC | APGE | Non-Voting Common Stock | Disposed to Issuer | -100% | -6,743,321 | 0 | 03 Sep 2026 | By Fairmount Healthcare Fund II LP | ||
| Fairmount Funds Management LLC | APGE | Non-Voting Common Stock | Disposed to Issuer | -100% | -6,743,321 | 0 | 03 Sep 2026 | By Fairmount Healthcare Fund II LP | ||
| Fairmount Funds Management LLC | APGE | Non-Voting Common Stock | Disposed to Issuer | -100% | -6,743,321 | 0 | 03 Sep 2026 | By Fairmount Healthcare Fund II LP | ||
| Fairmount Funds Management LLC | APGE | Non-Voting Common Stock | Disposed to Issuer | -100% | -6,743,321 | 0 | 03 Sep 2026 | By Fairmount Healthcare Fund II LP | ||
| Mark C. McKenna | APGE | Common Stock | Disposed to Issuer | -100% | -20,000 | 0 | 03 Sep 2026 | Direct | ||
| Mark C. McKenna | APGE | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -182,488 | 0 | 03 Sep 2026 | Direct | ||
| William A. Jones Jr. | APGE | Common Stock | Disposed to Issuer | -100% | -34,824 | 0 | 03 Sep 2026 | Direct | ||
| William A. Jones Jr. | APGE | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -32,488 | 0 | 03 Sep 2026 | Direct | ||
| Carl Dambkowski | APGE | Common Stock | Disposed to Issuer | -100% | -167,123 | 0 | 03 Sep 2026 | Direct | ||
| Carl Dambkowski | APGE | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -319,317 | 0 | 03 Sep 2026 | Direct | ||
| Jennifer A. Fox | APGE | Common Stock | Disposed to Issuer | -100% | -34,824 | 0 | 03 Sep 2026 | Direct | ||
| Jennifer A. Fox | APGE | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -32,488 | 0 | 03 Sep 2026 | Direct | ||
| Jane Pritchett Henderson | APGE | Common Stock | Disposed to Issuer | -100% | -158,371 | 0 | 03 Sep 2026 | Direct | ||
| Jane Pritchett Henderson | APGE | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -383,997 | 0 | 03 Sep 2026 | Direct | ||
| Lisa Bollinger | APGE | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -48,780 | 0 | 03 Sep 2026 | Direct | ||
| Michael Thomas Henderson | APGE | Common Stock | Disposed to Issuer | -100% | -920,941 | 0 | 03 Sep 2026 | Direct | ||
| Michael Thomas Henderson | APGE | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -997,064 | 0 | 03 Sep 2026 | Direct | ||
| Nimish P. Shah | APGE | Common Stock | Disposed to Issuer | -100% | -1,750,000 | 0 | 03 Sep 2026 | See footnote | ||
| Nimish P. Shah | APGE | Pre-Funded Warrants (Right to Buy) | Disposed to Issuer | -100% | -365,853 | 0 | 03 Sep 2026 | See footnote | ||
| Nimish P. Shah | APGE | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -80,246 | 0 | 03 Sep 2026 | Direct | ||
| Nimish P. Shah | APGE | Non-Voting Common Stock | Disposed to Issuer | -100% | -6,743,321 | 0 | 03 Sep 2026 | See footnote | ||
| Carl Dambkowski | APGE | Common Stock | Disposed to Issuer | -0.82% | -1,375 | 167,123 | 02 Sep 2026 | Direct | ||
| Fairmount Funds Management LLC | APGE | Common Stock | Options Exercise | 14.1% | 42,208 | 340,855 | 07 Aug 2026 | By Fairmount Healthcare Fund II LP | ||
| Fairmount Funds Management LLC | APGE | Common Stock | Options Exercise | 14.1% | 42,208 | 340,855 | 07 Aug 2026 | By Fairmount Healthcare Fund II LP | ||
| Fairmount Funds Management LLC | APGE | Common Stock | Options Exercise | 14.1% | 42,208 | 340,855 | 07 Aug 2026 | By Fairmount Healthcare Fund II LP | ||
| Fairmount Funds Management LLC | APGE | Common Stock | Options Exercise | 14.1% | 42,208 | 340,855 | 07 Aug 2026 | By Fairmount Healthcare Fund II LP | ||
| Fairmount Funds Management LLC | APGE | Stock Option (Right to Buy) | Options Exercise | -100% | -42,208 | 0 | 07 Aug 2026 | Direct | ||
| Fairmount Funds Management LLC | APGE | Stock Option (Right to Buy) | Options Exercise | -100% | -42,208 | 0 | 07 Aug 2026 | Direct | ||
| Fairmount Funds Management LLC | APGE | Stock Option (Right to Buy) | Options Exercise | -100% | -42,208 | 0 | 07 Aug 2026 | Direct | ||
| Fairmount Funds Management LLC | APGE | Stock Option (Right to Buy) | Options Exercise | -100% | -42,208 | 0 | 07 Aug 2026 | Direct | ||
| Carl Dambkowski | APGE | Common Stock | Sale | -3.16% | $737,935 | $134.17 | -5,500 | 168,498 | 05 Aug 2026 | Direct |
| Carl Dambkowski | APGE | Common Stock | Options Exercise | 2.43% | 4,125 | 173,998 | 05 Aug 2026 | Direct | ||
| Carl Dambkowski | APGE | Stock Option (Right to Buy) | Options Exercise | -3.59% | -4,125 | 110,665 | 05 Aug 2026 | Direct | ||
| Jane Pritchett Henderson | APGE | Common Stock | Gift | -8.65% | -15,000 | 158,371 | 24 Jul 2026 | Direct |
* marks a reported price that did not pass the local price check.